Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Thoracic 2Other hematologic neoplasm 2Dermatologic 2Breast 2Sarcoma 1Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Locally Advanced Pancreatic Adenocarcinoma 1

Interventions

Oxaliplatin 135Fluorouracil 129Gemcitabine 114Bevacizumab 111Specimen Handling 101Leucovorin 101Capecitabine 87Magnetic Resonance Spectroscopy 81pembrolizumab 78Cisplatin 74Nivolumab 70Irinotecan 68Cetuximab 58130-nm albumin-bound paclitaxel 58durvalumab 57Paclitaxel 57Biopsy 55atezolizumab 42Radiotherapy 40Albumin-Bound Paclitaxel 36Taxes 35Folfox protocol 34Carboplatin 34Drug Therapy 28lenvatinib 27sintilimab 26dehydroftorafur 26Radiation 26Cyclophosphamide 26tislelizumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
sargramostim × Gastrointestinal × 90 days × Clear all
NCT00669734 2026-04-23

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
18 enrolled
Gastrointestinal

Locally Advanced Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡